Regulatory T cells in the treatment of autoimmune myositis in mice: efficacy and mechanism.
- Author:
Qiang SHI
1
;
Cheng-Lin TIAN
;
Jie-Xiao LIU
;
Chuan-Qiang PU
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Autoimmune Diseases; immunology; CTLA-4 Antigen; metabolism; Cell Separation; Cell- and Tissue-Based Therapy; Disease Models, Animal; Flow Cytometry; Interleukin-10; blood; Mice; Myositis; immunology; Programmed Cell Death 1 Receptor; metabolism; Spleen; immunology; T-Lymphocytes, Regulatory; immunology; Transforming Growth Factor beta1; blood
- From: Journal of Southern Medical University 2015;35(4):602-605
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate effect of CD4(+) CD25(+) Foxp3(+) Tregs in the treatment of autoimmune myositis (EAM) in mice and explore the possible mechanisms.
METHODSMouse models of EAM were divided randomly into model group and treatment group, and the latter received infusion of CD4(+) CD25(+) Foxp3(+) Tregs separated from normal mouse spleen by magnetic activated cell sorting. The changes of muscle pathology was observed, and the expression of PD-1 and CTLA-4 in spleen CD4(+) CD25(+) Foxp3(+) Tregs was analyzed using flow cytometry; peripheral blood IL-10 and TGF-β levels were tested using double antibody sandwich ELISA.
RESULTSCompare with the model group, the mice in the treatment group showed significantly reduced muscular inflammatory cell infiltration, increased blood levels of IL-10 and TGF-β (P<0.05), and increased expression of PD-1 and CTLA-4 in spleen CD4(+) CD25(+) Foxp3(+) Tregs (P<0.05).
CONCLUSIONCD4(+) CD25(+) Foxp3(+) Tregs reinfusion produces therapeutic effect in mice with EAM by increasing peripheral blood IL-10 and TGF-β levels and PD-1 and CTLA-4 expressions in spleen CD4(+) CD25(+) Foxp3(+) Tregs.
